Sisällysluettelo:
“…Psychiatric Disorders in Children and Adolescents – Neurodevelopmental disorders – Autism Spectrum Disorder (ASD) -- Attention-Deficit/Hyperactivity Disorder (ADHD) -- Tourette's Disorder – Schizophrenia -- Bipolar Disorder (BD) -- Depressive Disorders -- Disruptive Mood Dysregulation Disorder (DMDD) -- Major Depressive Disorder (MDD) --Anxiety disorders -- Separation Anxiety Disorder -- Specific Phobia – Social Anxiety Disorder -- Panic Disorder --Generalized Anxiety Disorder (GAD) -- Obsessive-Compulsive Disorder (OCD) -- Posttraumatic Stress Disorder (PTSD -- Disruptive, impulse-control, and conduct disorders -- Oppositional Defiant Disorder (ODD) – Conduct Disorder (CD) – Syndrome: Catatonia -- Drugs for ADHD – Psychostimulants -- Atomoxetine -- Comparison of Drugs for ADHD -- α2 agonists -- Augmentation Strategies in ADHD – Antidepressants -- Selective Serotonin Reuptake Inhibitors (SSRI) -- Norepinephrine Dopamine Reuptake Inhibitor (NDRI) -- Serotonin Norepinephrine Reuptake Inhibitor (SNRI) -- Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) -- Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI) -- Serotonin Modulator and Stimulator (SMS) -- Noradrenergic/Specific Serotonergic Antidepressants (NaSSA) -- Nonselective Cyclic Antidepressants -- Monoamine Oxidase Inhibitors -- Reversible Inhibitor of MAO-A (RIMA) -- Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs) -- Irreversible MAO-B Inhibitor -- Effects of Antidepressants on Neurotransmitters/Receptors -- Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors -- Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses -- Antidepressant Doses and Pharmacokinetics -- Switching Antidepressants -- Antidepressant Augmentation Strategies -- Electroconvulsive Therapy (ECT) – Antipsychotics -- Second-Generation Antipsychotics/SGAs -- Third-Generation Antipsychotic/ TGA -- First-Generation Antipsychotics/FGAs -- Effects of Antipsychotics on Neurotransmitters/Receptors -- Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes -- Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses -- Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) -- Comparison of Long-Acting IM Antipsychotics -- Switching Antipsychotics -- Antipsychotic Augmentation Strategies -- Antipsychotic-Induced Extrapyramidal Side Effects (EPSE) and Their Management -- Extrapyramidal Side Effects of Antipsychotics -- Treatment Options for Extrapyramidal Side Effects -- Effects on Extrapyramidal Side Effects -- Comparison of Agents for Treating Acute Extrapyramidal Side Effects -- Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects -- Anxiolytic (Antianxiety) Agents – Benzodiazepines -- Comparison of the Benzodiazepines -- Buspirone -- Hypnotics/Sedatives -- Comparison of Hypnotics/Sedatives -- Mood Stabilizers – Lithium – Anticonvulsants -- Comparison of Anticonvulsants -- Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses -- Drugs/Substances of Abuse – Alcohol – Stimulants – Hallucinogens -- Opioids -- Inhalants/Aerosols -- Sodium Oxybate (Gamma-Hydroxybutyrate - GHB) -- Flunitrazepam (Rohypnol) -- Nicotine/Tobacco -- Treatment of Substance Use Disorders – Acamprosate -- Disulfiram –
Naltrexone – Buprenorphine – Methadone -- Pharmacotherapy for Nicotine/Tobacco Use Dependence -- Unapproved Treatments of Psychiatric Disorders -- Adrenergic Agents – Anti-inflammatory Agents -- Cholinergic Agents -- Dopaminergic Agents – NMDA Agents – Miscellaneous – Natural Health Products – Glossary – Drugs Use in Pregnancy and Effects on Breast Milk – Patient and Caregiver Information Sheets – Index of Drugs…”
Tallennettuna: